Moleculogic: deterministic therapeutic design & cryptographically verifiable drug development infrastructure
MetalDrug is advancing Moleculogic, a deterministic therapeutic design and programmable drug development infrastructure platform for biotechnology and pharmaceutical applications. Unlike traditional black-box AI drug discovery systems, Moleculogic encodes therapeutic intent as traceable physical and coordination chemistry constraints, enabling transparent, auditable, and cryptographically verifiable molecular design workflows.
The platform combines logic-driven molecular engineering, ADMET simulation layers, cryptographic proof anchoring, and secure blueprint validation infrastructure to support translational therapeutic development while protecting intellectual property. The architecture includes progressive simulation tiers, federated collaboration environments, ZK-verified molecular proof systems, and tokenized compute infrastructure designed for scalable enterprise and institutional deployment.
Current focus areas include:
Programmable therapeutics Metal-ligand therapeutic coordination systems Translational biotech infrastructure AI-enabled drug development workflows Regulatory-grade molecular validation Secure collaborative pharmaceutical R&D environments
We are seeking co-development partnerships, pilot collaborations, sponsored research relationships, strategic investment partners, and pharmaceutical/biotech organizations interested in next-generation computational biology infrastructure, deterministic therapeutic systems, and secure translational drug development platforms.
About MyMonitor Corporation
MyMonitor Corporation is a healthcare technology company that has developed an AI-driven platform designed to modernize dermatological assessment and clinical research. The system functions by converting standard skin images into structured, objective clinical data, aiming to reduce diagnostic variability and improve the precision of skin condition management. A core feature of the platform is its use of melanin-aware imaging technology, which is intended to support more equitable and inclusive diagnostics across diverse skin tones. Beyond image analysis, the platform provides tools that integrate with healthcare systems and electronic health records to streamline workflows for clinicians and stakeholders in the dermatological field.
This technology is intended to assist a wide range of organizations, including hospitals, clinics, and health systems, by enhancing diagnostic accuracy and facilitating more efficient patient care. Additionally, the platform addresses needs within clinical trials by offering smart recruitment strategies and ensuring diverse patient enrollment. By shifting dermatology toward a more data-driven approach, MyMonitor seeks to transform subjective visual assessments into measurable medical insights, ultimately aiming to improve patient outcomes and support research evidence generation from bedside to benchside. The company, which is based in the United States, focuses on closing the gap between traditional dermatological practice and modern data science.
Inquire about this partnering listing
Looking for
Industry applications
delivered to your inbox.